Shares soared 25%, AnPac Bio-Medical on first disease treatment US patent
Shares soared 25%, AnPac Bio-Medical on first disease treatment US patent
$AnPac Bio-Medical Science(ANPC.US)$ has received its first disease treatment patent by the United States Patent and Trademark Office.
$Anpac生物医学科学(ANPC.US)$已获得美国专利商标局的首项疾病治疗专利。
The patent covers novel medical devices for both disease detection and treatment applications and has 25 claims.
The patent covers novel device structures and methods to modify biological samples for treatment purposes. This latest patent is the 21st patent granted to AnPac Bio in the U.S.
The Company also announced that its newly launched cancer treatment joint venture has secured, via signed legal documents, over $4 million of capital contributions from multiple funding sources.
The funding will be used to fabricate cancer treatment medical devices and the device's subsequent laboratory tests this year.
Price Action: ANPC shares are up 25% at $5.42 during the premarket trading session on the last check Friday.
该专利涵盖了用于疾病检测和治疗的新型医疗设备，并提出了25项权利要求。
该专利涵盖了为治疗目的而修改生物样本的新型装置结构和方法。这项最新专利是安帕克生物公司在美国获得的第21项专利。
该公司还宣布，其新成立的癌症治疗合资企业已通过签署的法律文件从多个资金来源获得400多万美元的出资。
这笔资金将用于制造癌症治疗医疗设备，以及今年该设备随后的实验室测试。
价格行动：在周五最后一次盘前交易中，ANPC股价上涨25%，至5.42美元。